Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids

被引:129
作者
Saghazadeh, Amene [1 ,2 ]
Rezaei, Nima [1 ,3 ,4 ]
机构
[1] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran, Iran
[2] Universal Sci Educ & Res Network USERN, Systemat Review & Meta Anal Expert Grp SRMEG, Tehran, Iran
[3] Univ Tehran Med Sci, Sch Med, Dept Immunol & Biol, Tehran, Iran
[4] Universal Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Tehran, Iran
关键词
COVID-19; Treatment; Immunoglobulin; Targeted therapy; Corticosteroids; Interleukin; 6; VIRULENCE;
D O I
10.1016/j.intimp.2020.106560
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.
引用
收藏
页数:6
相关论文
共 34 条
[1]  
Andersen K.G., 2020, ARTIC NETWORK, V17
[2]   Global aspects of viral glycosylation [J].
Bagdonaite, Ieva ;
Wandall, Hans H. .
GLYCOBIOLOGY, 2018, 28 (07) :443-467
[3]  
Bergin C, 2020, INTERIM RECOMMENDATI
[4]  
Cao B, 2020, NEW ENGL J MED, V382
[5]  
Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.1
[6]   Type IIFN modulates innate and specific antiviral immunity [J].
Durbin, JE ;
Fernandez-Sesma, A ;
Lee, CK ;
Rao, TD ;
Frey, AB ;
Moran, TM ;
Vukmanovic, S ;
García-Sastre, A ;
Levy, DE .
JOURNAL OF IMMUNOLOGY, 2000, 164 (08) :4220-4228
[7]   Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections [J].
Ferrara, Giovanni ;
Zumla, Alimuddin ;
Maeurer, Markus .
AMERICAN JOURNAL OF MEDICINE, 2012, 125 (10)
[8]  
Hoffmann Markus, 2021, EBioMedicine, V65, P103255, DOI [10.1101/2020.08.05.237651, 10.1016/j.ebiom.2021.103255]
[9]   Tonsillar Kaposi sarcoma in a renal transplant patient [J].
Howard, John H., III ;
Darrow, Morgan ;
Chen, Ling-Xin ;
Alnimri, Muna ;
Jen, Kuang-Yu .
TRANSPLANT INFECTIOUS DISEASE, 2020, 22 (05)
[10]   COVID-19 spike-host cell receptor GRP78 binding site prediction [J].
Ibrahim, Ibrahim M. ;
Abdelmalek, Doaa H. ;
Elshahat, Mohammed E. ;
Elfiky, Abdo A. .
JOURNAL OF INFECTION, 2020, 80 (05) :554-562